[email protected]

Foresight Diagnostics announces $58.75 Million Series B financing led by Foresite Capital to commercialize ultrasensitive liquid biopsy MRD testing platform

Foresight Diagnostics Logo

Apr 27, 2023

AURORA, Colo.April 27, 2023 /PRNewswire/ — Foresight Diagnostics, Inc, a leading developer of ultrasensitive cancer detection tests, announced today that it has closed an oversubscribed Series B financing round of $58.75 million. The financing was led by Foresite Capital, with participation by Civilization Ventures, Bluebird Ventures, Pear Ventures, Agent Capital, Stanford University…

Read the full article on PR Newswire.


Share this page on social

Ready to get started? See what Samba can do for you.